By Patrick W. Serruys, Pedro A. Lemos
content material: SIROLIMUS-ELUTING STENTS within the medical perform: strategies AND normal assessment Sirolimus-Eluting Stents as an Anti-Restenosis gadget: uncomplicated ideas and precis of Pivotal stories, P.W. Serruys and P.A. Lemos Sirolimus-Eluting Stents within the "Real World": The study Registry purpose and learn layout, P.A. Lemos, P.W. Serruys, and R.T. van Domburg Unrestricted usage of Sirolimus-Eluting Stents for de Novo Coronary Lesions, P.A. Lemos, P.W. Serruys, and R.T. van Domburg SIROLIMUS-ELUTING STENTS FOR sufferers AT excessive medical hazard Early defense of Sirolimus-Eluting Stents for sufferers with Acute Coronary Syndromes, P.A. Lemos, C-h. Lee, and P.W. Serruys Sirolimus-Eluting Stents for sufferers with Acute Myocardial Infarction, F. Saia, P.A. Lemos, and P.W. Serruys Sirolimus-Eluting Stents for sufferers with Impaired Renal functionality, P.A. Lemos, R.T. van Domburg, and P.W. Serruys Sirolimus-Eluting Stents for sufferers with past Coronary skip Graft surgical procedure, A. Hoye and P.W. Serruys Sirolimus-Eluting Stents for major Left Coronary Artery disorder, C.A. Arampatzis and P.W. Serruys Sirolimus-Eluting Stents for sufferers with Multivessel Coronary ailment, C.A. Arampatzis and P.A. Lemos Sirolimus-Eluting Stents for Elderlies, M. Vijayakumar, P.A. Lemos, and P.W. Serruys SIROLIMUS-ELUTING STENTS FOR sufferers AT particular ANATOMIC teams Sirolimus-Eluting Stents for persistent overall Occlusions, A. Hoye, okay. Tanabe, and P.W. Serruys Sirolimus-Eluting Stents for extraordinarily Small Coronary Vessels, P.A. Lemos and P.W. Serruys Sirolimus-Eluting Stents for extraordinarily lengthy Lesions, M. Degertekin, C.A. Arampatzis, and P.A. Lemos Sirolimus-Eluting Stents for Bifurcation Lesions, okay. Tanabe, A. Hoye, and P.W. Serruys Sirolimus-Eluting Stents for Coronary Narrowings
Read or Download Sirolimus eluting stents : from research to clinical practice PDF
Best cardiovascular books
Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development
Simple and medical researchers from and academia aspect the preclinical, scientific, and regulatory rules at present used to evaluate the cardiac safeguard of recent medicinal drugs. The authors clarify the parameters of cardiac protection in any respect levels of medical examine and drug improvement, together with either the preclinical and pharmacogenomic points ordinarily and the medical methodologies and technical facets for investigational medications according to cardiac repolarization, as outlined via the period of the QTc period.
Cardiac Remodeling: Mechanisms and Treatment (Fundamental and Clinical Cardiology)
Exploring the factors, mechanisms, and pathophysiology of cardiac home improvement, this reference bargains unique descriptions of some of the parts of the transforming technique, in addition to new healing interventions and up to date and destiny customers for the therapy of cardiac home improvement.
Reflecting the 2010 Emergency Cardiovascular Care guidance, ACLS research consultant, 4th version deals an entire, full-color evaluation of complex cardiovascular lifestyles help. An easy-to-read technique covers every little thing from airway administration and rhythms and their administration to electric remedy, acute coronary syndromes, and acute stroke.
Echocardiography in Pediatric and Congenital Heart Disease: From Fetus to Adult
This entire textbook at the echocardiographic evaluate of pediatric and congenital center sickness has been up-to-date for a moment version with an emphasis on new applied sciences. This highly-illustrated full-color reference comprises over 1200 figures, and provides over six hundred videos on a better half site.
- Primary pulmonary hypertension
- Cardiac therapy
- A Guide to Neonatal and Pediatric ECGs
- Manual of Perioperative Care in Adult Cardiac Surgery, Fourth Edition
- Myocarditis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
- Making Sense of the ECG: A Hands-On Guide, Fourth Edition
Additional resources for Sirolimus eluting stents : from research to clinical practice
Sample text
The safety and the effectiveness of a strategy of unrestrictive utilization of sirolimuseluting stent is compared to a strategy utilizing conventional bare stent implantation. For a detailed description of the RESEARCH design, the reader is referred to Chapter 2. The angiographic success rate was similar in both groups. No further thrombotic stent occlusion was observed in the late followup. 2). 2 Oneyear cumulative risk of clinically driven target vessel revascularization in patients treated with bare stents before the introduction of SES (PreSES group) and in patients treated exclusively with SES implantation (SES Group).
Incidence of adverse events at 30 days in patients treated with bare stents versus patients treated with sirolimuseluting stents. 2 illustrates a case of a patient with highrisk unstable angina treated with SES. 25 ×8 mm [d]). At 6month followup, there was no angiographic evidence of neointimal proliferation (bottom). 47 It seems unlikely that the lower utilization of glycoprotein IIb/IIIa blockers in these group could be explained by a lower risk profile perceived during the procedure, since both the control and SES populations were equally composed predominantly by patients with acute MI or high grade unstable angina, with no significant difference in their diabetic status.
39,40,48 Regardless of these contradictory laboratory findings, SES were not associated with clinically relevant devicerelated complications in our series, with no modification of the risk profile for procedural failure or event occurrence. 36,37 In this context, a relatively delayed hazardous effect of the drug leading to an increase in ‘late’ thrombotic complications after the first week was not observed in our patients. The maintenance of the excellent shortterm results already achieved with conventional techniques is a key point for the validation of SES as a useful strategy in treatment of patients with acute coronary syndromes.